Amivantamab (FUT8-KO)
Based on 1 Customer Validation
Amivantamab (FUT8-KO) is an anti-EGFR-MET monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Amivantamab (FUT8-KO) inhibits ligand binding, promotes endocytosis and degradation of receptor-antibody complexes, and induces Fc-dependent cytokinesis in macrophages and antibody-dependent cytotoxicity in natural killer cells.
For research use only. We do not sell to patients.
- Purity: 98%
- Molecular Weight:145.88 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All EGFR Isoforms
More
Biological Activity
Human IgG1 kappa
Human
EGFR & c-Met
The most extensively characterized aberration in fucosyltransferase (FUT) function in cancer is FUT8-mediated core fucosylation. FUT8 is frequently upregulated in human tumors. Depletion of FUT8 effectively blocks tumor growth and metastasis.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
IgG1-kappa
ELISA, FACS, Functional assay
-
Loaded Amivantamab (FUT8-KO) on ProA biosensor, can bind EGFR Protein, Human (621a.a, HEK293, His, HY-P70613) with an affinity constant of 2.774E-08 M as determined in BLI assay.
Chemical Information
-
Appearance Liquid
-
Molecular Weight 145.88 kDa
-
Color Colorless to light yellow
-
SMILES
[Amivantamab (FUT8-KO)]
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (258 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Keunchil Park, et al. Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study. J Clin Oncol. 2021 Oct 20;39(30):3391-3402. [Content Brief]
[2]. Jiyeon Yun, et al. Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC. Cancer Discov. 2020 Aug;10(8):1194-1209. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)